Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5
Open accessThe DOI matches its Crossref record; 72 of the 74 references it cites were found in a registry or an index.
Abstract
Neutralizing antibodies play a central role in the prevention and clearance of viral infections, but can be detrimental to the use of viral capsids for gene delivery. Antibodies present a major hurdle for ongoing clinical trials using adeno-associated viruses (AAVs); however, relatively little is known about the antigenic epitopes of most AAV serotypes or the mechanism(s) of antibody-mediated neutralization. We developed panels of AAV mAbs by repeatedly immunizing mice with AAV serotype 1 (AAV1) capsids, or by sequentially immunizing with AAV1 followed by AAV5 capsids, in order to examine the efficiency and mechanisms of antibody-mediated neutralization. The antibodies were not cross-reactive between heterologous AAV serotypes except for a low level of recognition of AAV1 capsids by the AAV5 antibodies, probably due to the initial immunization with AAV1. The neutralization efficiency of different IgGs varied and Fab fragments derived from these antibodies were generally poorly neutralizing. The antibodies appeared to display various alternative mechanisms of neutralization, which included inhibition of receptor-binding and interference with a post-attachment step.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have shown that following AAV administration, antibodies produced in response were cross-reactive against other non-administered AAV capsid variants [71–73].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [73]
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Successful outcomes of AAV gene delivery have also been realized by direct injection into partially immune privileged tissues such as the retinal pigment epithelium (Maguire et al., 2008).”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“The different serotypes of AAV have viral proteins (VPs) that are ~60–90 % identical in amino acid sequence (Gao et al., 2003, 2004), with variations in capsid surface-oriented loops, resulting in alterations of antigenicity, tissue tropism and transduction efficiency (Govindasamy et al., 2006;…”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 3×
“…to virus neutralization has been recognized as a major barrier to clinical trials involving AAV in humans, and the role of cellular immunity is also becoming increasingly appreciated (Boutin et al., 2010; Breous et al., 2011; Calcedo et al., 2009; Mingozzi & High, 2011; van der Marel et al., 2011).”
BackgroundAdeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922 · cited 3×
“…as vectors for therapeutic gene delivery due to features that make them potentially attractive vectors, including high capsid stability and lack of pathogenicity (Allocca et al., 2006; Dai & Rabie, 2007; Grimm & Kay, 2003; Michelfelder & Trepel, 2009; Van Vliet et al., 2008; Wu et al., 2006b).”
BackgroundWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 2×
“…to virus neutralization has been recognized as a major barrier to clinical trials involving AAV in humans, and the role of cellular immunity is also becoming increasingly appreciated (Boutin et al., 2010; Breous et al., 2011; Calcedo et al., 2009; Mingozzi & High, 2011; van der Marel et al., 2011).”
BackgroundBurger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741 · cited 2×
“Other serotypes such as AAV1 and AAV5 have been less well characterized, but show enhanced transduction of certain tissues such as muscle, brain and/or haematopoietic stem cells compared with AAV2 (Burger et al., 2004; Chao et al., 2000; Davidson et al., 2000; Zabner et al., 2000; Zhong et al., 2006).”
BackgroundMarks, W. J., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 684 · cited 1×
“The AAV2 serotype is the best characterized and is also the capsid type with the largest number of ongoing clinical gene therapy trials (e.g. Grieger & Samulski, 2005; Marks et al., 2010; Mueller & Flotte, 2008; Scallan et al., 2003).”
BackgroundSui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., Moore, M. J., Tallarico, A. S. C., Olurinde, M., Choe, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307140101 · Cited by 550 · cited 1×
“The cells were washed extensively with cold growth medium and assayed for viral binding compared with a control well with no antibody added as measured by Alexa-488 fluorescence intensity using flow cytometry (Sui et al., 2004).”
MethodGene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 2×
“…antibodies can be formed after initial gene therapy application, and strategies for avoiding interference with those during a second round of delivery antibodies include administration of transgenes packaged by different, non-cross-reactive AAV serotypes (Halbert et al., 2000; Xiao et al., 1999).”
BackgroundDavidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 13×
“Studies of AAV2 examining a small number of mAbs or polyclonal anti-capsid antibodies show that antibody binding is affected by changes in a small number of amino acid positions within variable loops on the capsid surface (Huttner et al., 2003; Lochrie et al., 2006; Maersch et al., 2010; Moskalenko et al., 2000; Wobus…”
InfluentialSelf-citationAntibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)
Mallery, D. L., McEwan, W. A., Bidgood, S. R., Towers, G. J., Johnson, C. M., & James, L. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014074107 · Cited by 516 · cited 3×
“Antibodies may neutralize viruses by a variety of mechanisms that include capsid crosslinking, the direct or steric inhibition of receptor binding, the prevention or premature triggering of conformational changes necessary for infection, or enhancing endocytosis or complement binding (Dimmock, 1993; Klasse & Sattentau…”
BackgroundInsect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors
Urabe, M., Ding, C., & Kotin, R. M. (2002) · Human Gene Therapy · doi:10.1089/10430340260355347 · Cited by 457 · cited 2×
“Empty (no DNA) AAV1 and AAV5 VLPs were composed of VP1, VP2 and VP3 expressed from baculoviruses under the control of the polyhedron promoter, produced in Hi5 insect cells, and purified using CsCl and sucrose gradients as described previously (DiMattia et al., 2005; Miller et al., 2006; Urabe et al., 2002).”
MethodKaludov, N., Brown, K. E., Walters, R. W., Zabner, J., & Chiorini, J. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6884-6893.2001 · Cited by 427 · cited 1×
“Both of these serotypes utilize sialic acids as their primary cellular receptors and AAV5 also binds to the platelet-derived growth factor receptor (PDGFR) as a co-receptor (Kaludov et al., 2001; Di Pasquale et al., 2003; Walters et al., 2001; Wu et al., 2006c).”
BackgroundSelf-citationChao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366 · cited 13×
“Studies of AAV2 examining a small number of mAbs or polyclonal anti-capsid antibodies show that antibody binding is affected by changes in a small number of amino acid positions within variable loops on the capsid surface (Huttner et al., 2003; Lochrie et al., 2006; Maersch et al., 2010; Moskalenko et al., 2000; Wobus…”
BackgroundInfluentialBinding of Adeno-associated Virus Type 5 to 2,3-Linked Sialic Acid Is Required for Gene Transfer
Walters, R. W., Yi, S. M. P., Keshavjee, S., Brown, K. E., Welsh, M. J., Chiorini, J. A., & Zabner, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101559200 · Cited by 363 · cited 1×
“Both of these serotypes utilize sialic acids as their primary cellular receptors and AAV5 also binds to the platelet-derived growth factor receptor (PDGFR) as a co-receptor (Kaludov et al., 2001; Di Pasquale et al., 2003; Walters et al., 2001; Wu et al., 2006c).”
BackgroundSelf-citationIdentification of PDGFR as a receptor for AAV-5 transduction
Pasquale, G. D., Davidson, B. L., Stein, C. S., Martins, I., Scudiero, D., Monks, A., & Chiorini, J. A. (2003) · Nature Medicine · doi:10.1038/nm929 · Cited by 355 · cited 1×
“Both of these serotypes utilize sialic acids as their primary cellular receptors and AAV5 also binds to the platelet-derived growth factor receptor (PDGFR) as a co-receptor (Kaludov et al., 2001; Di Pasquale et al., 2003; Walters et al., 2001; Wu et al., 2006c).”
BackgroundSelf-citationGrimm, D., & Kay, M. (2003) · Current Gene Therapy · doi:10.2174/1566523034578285 · Cited by 350 · cited 1×
“…as vectors for therapeutic gene delivery due to features that make them potentially attractive vectors, including high capsid stability and lack of pathogenicity (Allocca et al., 2006; Dai & Rabie, 2007; Grimm & Kay, 2003; Michelfelder & Trepel, 2009; Van Vliet et al., 2008; Wu et al., 2006b).”
BackgroundWu, Z., Miller, E., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00895-06 · Cited by 328 · cited 3×
“…as vectors for therapeutic gene delivery due to features that make them potentially attractive vectors, including high capsid stability and lack of pathogenicity (Allocca et al., 2006; Dai & Rabie, 2007; Grimm & Kay, 2003; Michelfelder & Trepel, 2009; Van Vliet et al., 2008; Wu et al., 2006b).”
BackgroundSelf-citationImmune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Adeno-associated viruses undergo substantial evolution in primates during natural infections
Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J., Abbas, Z., & Wilson, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937739100 · Cited by 323 · cited 1×
“The different serotypes of AAV have viral proteins (VPs) that are ~60–90 % identical in amino acid sequence (Gao et al., 2003, 2004), with variations in capsid surface-oriented loops, resulting in alterations of antigenicity, tissue tropism and transduction efficiency (Govindasamy et al., 2006;…”
BackgroundZabner, J., Seiler, M., Walters, R., Kotin, R. M., Fulgeras, W., Davidson, B. L., & Chiorini, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3852-3858.2000 · Cited by 315 · cited 13×
“Studies of AAV2 examining a small number of mAbs or polyclonal anti-capsid antibodies show that antibody binding is affected by changes in a small number of amino acid positions within variable loops on the capsid surface (Huttner et al., 2003; Lochrie et al., 2006; Maersch et al., 2010; Moskalenko et al., 2000; Wobus…”
BackgroundInfluentialSelf-citationClinical gene therapy using recombinant adeno-associated virus vectors
Mueller, C., & Flotte, T. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.68 · Cited by 313 · cited 1×
“The AAV2 serotype is the best characterized and is also the capsid type with the largest number of ongoing clinical gene therapy trials (e.g. Grieger & Samulski, 2005; Marks et al., 2010; Mueller & Flotte, 2008; Scallan et al., 2003).”
BackgroundOccupancy and mechanism in antibody-mediated neutralization of animal viruses
Klasse, P. J., & Sattentau, Q. J. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-9-2091 · Cited by 287 · cited 1×
“…capsid varies between different viruses, and may depend on epitope accessibility and organization as well as the overall capsid size, but the number of antibodies needed to neutralize effectively is generally proportional to the viral surface area (Klasse & Sattentau, 2002; Pierson et al., 2008).”
BackgroundPierson, T. C., Fremont, D. H., Kuhn, R. J., & Diamond, M. S. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.08.004 · Cited by 281 · cited 2×
“…capsid varies between different viruses, and may depend on epitope accessibility and organization as well as the overall capsid size, but the number of antibodies needed to neutralize effectively is generally proportional to the viral surface area (Klasse & Sattentau, 2002; Pierson et al., 2008).”
BackgroundWobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9281-9293.2000 · Cited by 273 · cited 8×
“Studies of AAV2 examining a small number of mAbs or polyclonal anti-capsid antibodies show that antibody binding is affected by changes in a small number of amino acid positions within variable loops on the capsid surface (Huttner et al., 2003; Lochrie et al., 2006; Maersch et al., 2010; Moskalenko et al., 2000; Wobus…”
BackgroundMethodResultInfluentialThe antiviral activity of antibodies in vitro and in vivo
Parren, P. W. H. I., & Burton, D. R. (2001) · Advances in Immunology · doi:10.1016/s0065-2776(01)77018-6 · Cited by 261 · cited 1×
“…of receptor binding, the prevention or premature triggering of conformational changes necessary for infection, or enhancing endocytosis or complement binding (Dimmock, 1993; Klasse & Sattentau, 2001; Law & Hangartner, 2008; Mallery et al., 2010; Parren & Burton, 2001; Willey & Aasa-Chapman, 2008).”
BackgroundHalbert, C. L., Rutledge, E. A., Allen, J. M., Russell, D. W., & Miller, A. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.3.1524-1532.2000 · Cited by 259 · cited 4×
“…antibodies can be formed after initial gene therapy application, and strategies for avoiding interference with those during a second round of delivery antibodies include administration of transgenes packaged by different, non-cross-reactive AAV serotypes (Halbert et al., 2000; Xiao et al., 1999).”
BackgroundMethodInfluentialStructure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector
Nam, H.-J., Lane, M. D., Padron, E., Gurda, B., McKenna, R., Kohlbrenner, E., Aslanidi, G., Byrne, B., Muzyczka, N., Zolotukhin, S., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01304-07 · Cited by 255 · cited 1×
“…identical in amino acid sequence (Gao et al., 2003, 2004), with variations in capsid surface-oriented loops, resulting in alterations of antigenicity, tissue tropism and transduction efficiency (Govindasamy et al., 2006; Lerch et al., 2010; Lochrie et al., 2006; Nam et al., 2007; Ng et al., 2010).”
BackgroundSelf-citationMoskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., & Patel, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1761-1766.2000 · Cited by 253 · cited 3×
“Studies of AAV2 examining a small number of mAbs or polyclonal anti-capsid antibodies show that antibody binding is affected by changes in a small number of amino acid positions within variable loops on the capsid surface (Huttner et al., 2003; Lochrie et al., 2006; Maersch et al., 2010; Moskalenko et al., 2000; Wobus…”
BackgroundResultWu, Z., Asokan, A., Grieger, J. C., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.01288-06 · Cited by 237 · cited 3×
“…as vectors for therapeutic gene delivery due to features that make them potentially attractive vectors, including high capsid stability and lack of pathogenicity (Allocca et al., 2006; Dai & Rabie, 2007; Grimm & Kay, 2003; Michelfelder & Trepel, 2009; Van Vliet et al., 2008; Wu et al., 2006b).”
BackgroundSelf-citationSubcellular compartmentalization of adeno-associated virus type 2 assembly
Wistuba, A., Kern, A., Weger, S., Grimm, D., & Kleinschmidt, J. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.2.1341-1352.1997 · Cited by 219 · cited 3×
“Mechanisms of antibody binding and neutralization of parvoviruses have been examined for AAV2 and for the autonomous parvoviruses canine parvovirus (CPV) and minute virus of mice (MVM) (López-Bueno et al., 2003; Murphy et al., 2009; Strassheim et al., 1994; Wistuba et al., 1997; Wobus et al., 2000).”
BackgroundImmune responses to adeno-associated virus and its recombinant vectors.
Sun, J. Y., Anand-Jawa, V, Chatterjee, S., & Wong, K. K. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302039 · Cited by 215 · cited 2×
“11 On: Wed, 20 Mar 2019 20:40:19 expression level and promoter of the transgene product (Breous et al., 2011; Hernandez et al., 1999; Li et al., 2008; Sun et al., 2003).”
BackgroundInfluentialMonteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206 · cited 1×
“Concurrent immunosuppressant (e.g. cyclosporin) administration or plasmapheresis along with the AAV vector may also temporarily reduce immune responses to the virus capsid and/or transgene (Lorain et al., 2008; Monteilhet et al., 2011).”
BackgroundStructurally mapping the diverse phenotype of adeno-associated virus serotype 4
Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J. A., & Agbandje-McKenna, M. (2006) · Journal of Virology · doi:10.1128/jvi.01536-06 · Cited by 205 · cited 1×
“…identical in amino acid sequence (Gao et al., 2003, 2004), with variations in capsid surface-oriented loops, resulting in alterations of antigenicity, tissue tropism and transduction efficiency (Govindasamy et al., 2006; Lerch et al., 2010; Lochrie et al., 2006; Nam et al., 2007; Ng et al., 2010).”
BackgroundSelf-citationLochrie, M. A., Tatsuno, G. P., Christie, B., McDonnell, J. W., Zhou, S., Surosky, R., Pierce, G. F., & Colosi, P. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.821-834.2006 · Cited by 201 · cited 7×
“Studies of AAV2 examining a small number of mAbs or polyclonal anti-capsid antibodies show that antibody binding is affected by changes in a small number of amino acid positions within variable loops on the capsid surface (Huttner et al., 2003; Lochrie et al., 2006; Maersch et al., 2010; Moskalenko et al., 2000; Wobus…”
BackgroundInfluential(2008) · PubMed Central · Cited by 183
Neutralization of Animal Viruses
Dimmock, N. J. (1993) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-77849-0 · Cited by 180
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge
Zaiss, A. K., & Muruve, D. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.54 · Cited by 180 · cited 1×
“Anti-AAV2 neutralizing antibodies have been detected in between 30 and 80 % of human subjects in different studies, and these antibodies are capable of neutralizing the virus and preventing transgene expression (Boutin et al., 2010; Lin et al., 2008; Petry et al., 2008; Zaiss & Muruve, 2008).”
BackgroundStrassheim, M. L., Gruenberg, A., Veijalainen, P., Sgro, J.-Y., & Parrish, C. R. (1994) · Virology · doi:10.1006/viro.1994.1020 · Cited by 175 · cited 1×
“…of antibody binding and neutralization of parvoviruses have been examined for AAV2 and for the autonomous parvoviruses canine parvovirus (CPV) and minute virus of mice (MVM) (López-Bueno et al., 2003; Murphy et al., 2009; Strassheim et al., 1994; Wistuba et al., 1997; Wobus et al., 2000).”
BackgroundSelf-citationHernandez, Y. J., Wang, J., Kearns, W. G., Loiler, S., Poirier, A., & Flotte, T. R. (1999) · Journal of Virology · doi:10.1128/jvi.73.10.8549-8558.1999 · Cited by 169 · cited 2×
“11 On: Wed, 20 Mar 2019 20:40:19 expression level and promoter of the transgene product (Breous et al., 2011; Hernandez et al., 1999; Li et al., 2008; Sun et al., 2003).”
BackgroundInfluentialGrieger, J. C., & Samulski, R. J. (2005) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_005 · Cited by 159 · cited 1×
“The AAV2 serotype is the best characterized and is also the capsid type with the largest number of ongoing clinical gene therapy trials (e.g. Grieger & Samulski, 2005; Marks et al., 2010; Mueller & Flotte, 2008; Scallan et al., 2003).”
BackgroundConway, J. E., Rhys, C. A., Zolotukhin, I., Zolotukhin, S., Muzyczka, N., Hayward, G. S., & Byrne, B. J. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300937 · Cited by 158 · cited 2×
“GFP-pseudopackaged AAV1 (rAAV1–GFP) and AAV5 (rAAV5–GFP) capsids were prepared as described previously (Conway et al., 1999).”
MethodAdeno-Associated Viral Vectors and Their Redirection to Cell-Type Specific Receptors
Michelfelder, S., & Trepel, M. (2009) · Advances in genetics · doi:10.1016/s0065-2660(09)67002-4 · Cited by 149 · cited 1×
“…as vectors for therapeutic gene delivery due to features that make them potentially attractive vectors, including high capsid stability and lack of pathogenicity (Allocca et al., 2006; Dai & Rabie, 2007; Grimm & Kay, 2003; Michelfelder & Trepel, 2009; Van Vliet et al., 2008; Wu et al., 2006b).”
BackgroundStructural Characterization of the Dual Glycan Binding Adeno-Associated Virus Serotype 6
Ng, R., Govindasamy, L., Gurda, B. L., McKenna, R., Kozyreva, O. G., Samulski, R. J., Parent, K. N., Baker, T. S., & Agbandje-McKenna, M. (2010) · Journal of Virology · doi:10.1128/jvi.01235-10 · Cited by 143 · cited 1×
“…identical in amino acid sequence (Gao et al., 2003, 2004), with variations in capsid surface-oriented loops, resulting in alterations of antigenicity, tissue tropism and transduction efficiency (Govindasamy et al., 2006; Lerch et al., 2010; Lochrie et al., 2006; Nam et al., 2007; Ng et al., 2010).”
BackgroundSelf-citationParrish, C. R., & Carmichael, L. E. (1983) · Virology · doi:10.1016/0042-6822(83)90179-4 · Cited by 142 · cited 1×
“Three days later the spleen lymphocytes were fused to mouse myeloma Sp2/0 cells according to standard methods using polyethylene glycol to create antibody-secreting hybridomas (Parrish & Carmichael, 1983).”
MethodSelf-citationHuttner, N. A., Girod, A., Perabo, L., Edbauer, D., Kleinschmidt, J. A., Büning, H., & Hallek, M. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302123 · Cited by 124 · cited 2×
“Studies of AAV2 examining a small number of mAbs or polyclonal anti-capsid antibodies show that antibody binding is affected by changes in a small number of amino acid positions within variable loops on the capsid surface (Huttner et al., 2003; Lochrie et al., 2006; Maersch et al., 2010; Moskalenko et al., 2000; Wobus…”
BackgroundSabo, M. C., Luca, V. C., Prentoe, J. C., Hopcraft, S. E., Blight, K. J., Yi, M., Lemon, S. M., Ball, J., Bukh, J., Evans, M. J., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00586-11 · Cited by 122
The Role of the Adeno-Associated Virus Capsid in Gene Transfer
Van Vliet, K. M., Blouin, V., Brument, N., Agbandje-McKenna, M., & Snyder, R. O. (2008) · Methods in Molecular Biology™ · doi:10.1007/978-1-59745-210-6_2 · Cited by 116 · cited 2×
“Several of the 12 currently identified AAV serotypes are under investigation as vectors for therapeutic gene delivery due to features that make them potentially attractive vectors, including high capsid stability and lack of pathogenicity (Allocca et al., 2006; Dai & Rabie, 2007; Grimm & Kay, 2003; Michelfelder & Trep…”
BackgroundSelf-citationLerch, T. F., Xie, Q., & Chapman, M. S. (2010) · Virology · doi:10.1016/j.virol.2010.03.027 · Cited by 106 · cited 1×
“…identical in amino acid sequence (Gao et al., 2003, 2004), with variations in capsid surface-oriented loops, resulting in alterations of antigenicity, tissue tropism and transduction efficiency (Govindasamy et al., 2006; Lerch et al., 2010; Lochrie et al., 2006; Nam et al., 2007; Ng et al., 2010).”
BackgroundJohnson, J. S., Li, C., DiPrimio, N., Weinberg, M. S., McCown, T. J., & Samulski, R. J. (2010) · Journal of Virology · doi:10.1128/jvi.00687-10 · Cited by 105 · cited 1×
“The highest titre fractions were identified by qPCR and TCID50 analysis in Cos-1 or HeLa cells (Johnson et al., 2010).”
Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector
Scallan, C. D., Lillicrap, D., Jiang, H., Qian, X., Patarroyo-White, S. L., Parker, A. E., Liu, T., Vargas, J., Nagy, D., Powell, S. K., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0292 · Cited by 103 · cited 1×
“The AAV2 serotype is the best characterized and is also the capsid type with the largest number of ongoing clinical gene therapy trials (e.g. Grieger & Samulski, 2005; Marks et al., 2010; Mueller & Flotte, 2008; Scallan et al., 2003).”
BackgroundDiverse IgG subclass responses to adeno‐associated virus infection and vector administration
Murphy, S. L., Li, H., Mingozzi, F., Sabatino, D. E., Hui, D. J., Edmonson, S. A., & High, K. A. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21360 · Cited by 101 · cited 3×
“Mechanisms of antibody binding and neutralization of parvoviruses have been examined for AAV2 and for the autonomous parvoviruses canine parvovirus (CPV) and minute virus of mice (MVM) (López-Bueno et al., 2003; Murphy et al., 2009; Strassheim et al., 1994; Wistuba et al., 1997; Wobus et al., 2000).”
BackgroundStructural Comparison of Different Antibodies Interacting with Parvovirus Capsids
Hafenstein, S., Bowman, V. D., Sun, T., Nelson, C. D. S., Palermo, L. M., Chipman, P. R., Battisti, A. J., Parrish, C. R., & Rossmann, M. G. (2009) · Journal of Virology · doi:10.1128/jvi.02532-08 · Cited by 81 · cited 1×
“IgG and ELISA and/or immunofluorescence confirmed Fab specificity and reactivity (Hafenstein et al., 2009).”
Self-citationDevelopment of AAV serotype-specific ELISAs using novel monoclonal antibodies
Kuck, D., Kern, A., & Kleinschmidt, J. A. (2007) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.10.005 · Cited by 74 · cited 3×
“The variability in neutralizing antibody efficacy and mechanism seen here echo previous results with antibodies directed against other AAV serotypes, and highlight the need to further clarify the key epitopes on the AAV capsid surface (Kuck et al., 2007; Moskalenko et al., 2000; Wobus et al., 2000).”
BackgroundMethodResultLópez-Bueno, A., Mateu, M. G., & Almendral, J. M. (2003) · Journal of Virology · doi:10.1128/jvi.77.4.2701-2708.2003 · Cited by 73 · cited 3×
“Mechanisms of antibody binding and neutralization of parvoviruses have been examined for AAV2 and for the autonomous parvoviruses canine parvovirus (CPV) and minute virus of mice (MVM) (López-Bueno et al., 2003; Murphy et al., 2009; Strassheim et al., 1994; Wistuba et al., 1997; Wobus et al., 2000).”
BackgroundMechanisms of Virus Neutralization by Antibody
Klasse, P. J., & Sattentau, Q. J. (2001) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-05783-4_6 · Cited by 69 · cited 1×
“…of receptor binding, the prevention or premature triggering of conformational changes necessary for infection, or enhancing endocytosis or complement binding (Dimmock, 1993; Klasse & Sattentau, 2001; Law & Hangartner, 2008; Mallery et al., 2010; Parren & Burton, 2001; Willey & Aasa-Chapman, 2008).”
BackgroundPetry, H., Brooks, A. R., Orme, A. E., Wang, P., Liu, P., Xie, J., Kretschmer, P. J., Qian, H. S., Hermiston, T. W., & Harkins, R. N. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303037 · Cited by 68 · cited 1×
“Anti-AAV2 neutralizing antibodies have been detected in between 30 and 80 % of human subjects in different studies, and these antibodies are capable of neutralizing the virus and preventing transgene expression (Boutin et al., 2010; Lin et al., 2008; Petry et al., 2008; Zaiss & Muruve, 2008).”
BackgroundLorain, S., Gross, D.-A., Goyenvalle, A., Danos, O., Davoust, J., & Garcia, L. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300377 · Cited by 62 · cited 2×
“Concurrent immunosuppressant (e.g. cyclosporin) administration or plasmapheresis along with the AAV vector may also temporarily reduce immune responses to the virus capsid and/or transgene (Lorain et al., 2008; Monteilhet et al., 2011).”
BackgroundHumoral immunity to HIV-1: neutralisation and antibody effector functions
Willey, S., & Aasa-Chapman, M. M. I. (2008) · Trends in Microbiology · doi:10.1016/j.tim.2008.08.008 · Cited by 59 · cited 1×
“…of receptor binding, the prevention or premature triggering of conformational changes necessary for infection, or enhancing endocytosis or complement binding (Dimmock, 1993; Klasse & Sattentau, 2001; Law & Hangartner, 2008; Mallery et al., 2010; Parren & Burton, 2001; Willey & Aasa-Chapman, 2008).”
BackgroundMiller, E. B., Gurda-Whitaker, B., Govindasamy, L., McKenna, R., Zolotukhin, S., Muzyczka, N., & Agbandje-McKenna, M. (2006) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309106048184 · Cited by 58
Self-citationHarbison, C. E., Lyi, S. M., Weichert, W. S., & Parrish, C. R. (2009) · Journal of Virology · doi:10.1128/jvi.00295-09 · Cited by 57 · cited 2×
“AAV1 and AAV5 VLPs were fluorescently labelled with Alexa-488 dyes (Invitrogen), following the manufacturer’s instructions, with purification as described previously (Harbison et al., 2009).”
MethodSelf-citationLin, J., Calcedo, R., Vandenberghe, L. H., Figueredo, J. M., & Wilson, J. M. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.033 · Cited by 53 · cited 1×
“Anti-AAV2 neutralizing antibodies have been detected in between 30 and 80 % of human subjects in different studies, and these antibodies are capable of neutralizing the virus and preventing transgene expression (Boutin et al., 2010; Lin et al., 2008; Petry et al., 2008; Zaiss & Muruve, 2008).”
BackgroundOptimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes
Maersch, S., Huber, A., Büning, H., Hallek, M., & Perabo, L. (2010) · Virology · doi:10.1016/j.virol.2009.10.021 · Cited by 50 · cited 2×
“Studies of AAV2 examining a small number of mAbs or polyclonal anti-capsid antibodies show that antibody binding is affected by changes in a small number of amino acid positions within variable loops on the capsid surface (Huttner et al., 2003; Lochrie et al., 2006; Maersch et al., 2010; Moskalenko et al., 2000; Wobus…”
BackgroundAntibodies against viruses: passive and active immunization
Law, M., & Hangartner, L. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.005 · Cited by 48 · cited 1×
“…of receptor binding, the prevention or premature triggering of conformational changes necessary for infection, or enhancing endocytosis or complement binding (Dimmock, 1993; Klasse & Sattentau, 2001; Law & Hangartner, 2008; Mallery et al., 2010; Parren & Burton, 2001; Willey & Aasa-Chapman, 2008).”
BackgroundAnderson, R. W., Macdonald, I., Corbett, T., Whiteway, A., & Prentice, H. G. (2000) · Journal of Virological Methods · doi:10.1016/s0166-0934(99)00150-0 · Cited by 48 · cited 1×
“The bound antibody-conjugated HRP was detected with Supersignal luminescent substrate (Thermo Scientific) and exposed to X-ray film (Anderson et al., 2000).”
MethodAAV-mediated gene transfer for retinal diseases
Allocca, M., Tessitore, A., Cotugno, G., & Auricchio, A. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.12.1279 · Cited by 44 · cited 2×
“Several of the 12 currently identified AAV serotypes are under investigation as vectors for therapeutic gene delivery due to features that make them potentially attractive vectors, including high capsid stability and lack of pathogenicity (Allocca et al., 2006; Dai & Rabie, 2007; Grimm & Kay, 2003; Michelfelder & Trep…”
BackgroundPetry, H., Orme, A., Liu, P., Bauzone, M., Gibson, H., Qian, H., Rubanyi, G. M., & Harkins, R. N. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.1088 · Cited by 43
DiMattia, M., Govindasamy, L., Levy, H. C., Gurda-Whitaker, B., Kalina, A., Kohlbrenner, E., Chiorini, J. A., McKenna, R., Muzyczka, N., Zolotukhin, S., et al. (2005) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309105028514 · Cited by 42 · cited 1×
“…DNA) AAV1 and AAV5 VLPs were composed of VP1, VP2 and VP3 expressed from baculoviruses under the control of the polyhedron promoter, produced in Hi5 insect cells, and purified using CsCl and sucrose gradients as described previously (DiMattia et al., 2005; Miller et al., 2006; Urabe et al., 2002).”
MethodSelf-citationBreous, E., Somanathan, S., Bell, P., & Wilson, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.002 · Cited by 40 · cited 4×
“…to virus neutralization has been recognized as a major barrier to clinical trials involving AAV in humans, and the role of cellular immunity is also becoming increasingly appreciated (Boutin et al., 2010; Breous et al., 2011; Calcedo et al., 2009; Mingozzi & High, 2011; van der Marel et al., 2011).”
BackgroundInfluentialvan der Marel, S., Comijn, E. M., Verspaget, H. W., van Deventer, S., van den Brink, G. R., Petry, H., Hommes, D. W., & Ferreira, V. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21673 · Cited by 34 · cited 2×
“…to virus neutralization has been recognized as a major barrier to clinical trials involving AAV in humans, and the role of cellular immunity is also becoming increasingly appreciated (Boutin et al., 2010; Breous et al., 2011; Calcedo et al., 2009; Mingozzi & High, 2011; van der Marel et al., 2011).”
BackgroundMethodZhong, L., Li, W., Li, Y., Zhao, W., Wu, J., Li, B., Maina, N., Bischof, D., Qing, K., Weigel-Kelley, K. A., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.321 · Cited by 32 · cited 1×
“…serotypes such as AAV1 and AAV5 have been less well characterized, but show enhanced transduction of certain tissues such as muscle, brain and/or haematopoietic stem cells compared with AAV2 (Burger et al., 2004; Chao et al., 2000; Davidson et al., 2000; Zabner et al., 2000; Zhong et al., 2006).”
BackgroundThe use of recombinant adeno-associated virus for skeletal gene therapy.
Dai, J., & Rabie, A. (2007) · Orthodontics & craniofacial research · doi:10.1111/j.1601-6343.2007.00381.x · Cited by 25 · cited 1×
“…as vectors for therapeutic gene delivery due to features that make them potentially attractive vectors, including high capsid stability and lack of pathogenicity (Allocca et al., 2006; Dai & Rabie, 2007; Grimm & Kay, 2003; Michelfelder & Trepel, 2009; Van Vliet et al., 2008; Wu et al., 2006b).”
Background
Research works printed but not linked: 2
- 10.1073/pnas.050581197 · DOI · Paper page
- Kerr, 2006, Parvoviruses
Cited by
Tse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704766114 · Cited by 210
“An earlier study showed that 4E4 and 5H7 reduce AAV1 transduction by affecting both the binding and postattachment steps essential for host cell transduction (6).”
BackgroundMethodSelf-citationImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
Tseng, Y.-S., & Agbandje-McKenna, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00009 · Cited by 134
“This is because the MAb was generated only 4 days after AAV5 capsid immunization of a mouse that had been previously immunized with AAV1 (56).”
BackgroundInfluentialSelf-citationCapsid antibodies to different adeno-associated virus serotypes bind common regions
Gurda, B. L., DiMattia, M. A., Miller, E. B., Bennett, A., McKenna, R., Weichert, W. S., Nelson, C. D., Chen, W.-J., Muzyczka, N., Olson, N. H., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00622-13 · Cited by 127
Self-citationMoreno, A. M., Palmer, N., Alemán, F., Chen, G., Pla, A., Jiang, N., Leong Chew, W., Law, M., & Mali, P. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0431-2 · Cited by 125
Metadata
- Authors
- Harbison, C. E., Weichert, W. S., Gurda, B. L., Chiorini, J. A., Agbandje-McKenna, M., & Parrish, C. R.
- Affiliations
- Cornell University (US)
- University of Florida (US)
- National Institutes of Health (US)
- Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL 32610, USA
- Venue
- Journal of General Virology
- Publisher
- Microbiology Society
- Published
- 2012-02-01
- Volume
- 93
- Issue
- 2
- Pages
- 347-355
- ISSN
- 0022-1317 (ISSN-L)
- 1465-2099
- PMC
- PMC3352341
- OpenAlex
- W2127304128
- Cited by
- 54
- References
- 74
- Citations by year
- 2025: 6 · 2024: 1 · 2023: 3 · 2022: 6 · 2021: 2 · 2020: 5 · 2019: 5 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 3 · 2012: 3
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of General Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL059412)
- National Institute of Allergy and Infectious Diseases (R21AI072341)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, AAV1, AAV5, monoclonal antibodies, antibody neutralization, cross-reactivity, viral capsid, gene delivery vectors, receptor binding inhibition, Fab fragment, vaccination strategies
- MeSH terms
- Dependovirus, Animals, Antibodies, Monoclonal, Antibodies, Viral, Cross Reactions, Immunoglobulin G, Neutralization Tests, Mice, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.